Piperaquine Survival Assays (PSA) to evaluate the in-vitro and ex-vivo susceptibility of Plasmodium falciparum to piperaquine

This procedure describes two assays to evaluate the susceptibility of Plasmodium falciparum to piperaquine.

 

 

Publication Version
V1.0
Publication Code
INV11

This procedure describes two assays to evaluate the susceptibility of Plasmodium falciparum to piperaquine. The in-vitro Piperaquine Survival Assay (PSA) is performed on 0-3 hour post-invasion rings obtained from culture-adapted parasites. The ex-vivo Piperaquine Survival Assay (ex-vivo PSA) is performed on parasite isolates freshly collected from patients with malaria. In both assays, parasites are exposed to 200 nM piperaquine (PPQ) for 48 hours – approximating their drug exposure in patients treated with piperaquine based ACT – and their survival is assessed 72 hours later as described in Duru et al. 2015 

Attachments